Skip to content
FIND A HEALTH VALLEY ACTOR

HUG to test a promising messenger RNA vaccine against melanoma

HUG RNA Vaccine

A messenger RNA vaccine developed by Moderna, which has recently been shown to be effective against certain cases of melanoma, will soon be tested in Geneva. The HUG hopes to start the clinical trial in the summer or autumn of 2023.     “The University Hospitals of Geneva (HUG) are one of the centres –…

Read More

Swiss and American researchers reached a potential milestone in cancer therapy

Inselspital

Researchers from the University of Bern, Inselspital, University Hospital Bern, and the University of Connecticut have made a significant breakthrough in the fight against cancer. They identified a previously unknown weak point of prostate cancer cells. This could also lead to entirely new therapeutic approaches for other types of cancer.   Prostate cancer is the…

Read More

Merck inaugurates its Biotech Development Centre in Corsier-sur-Vevey

Merck Biotech Development Center

German laboratory Merck invested CHF 250 million in Corsier-sur-Vevey (VD). The 15,700 m2 building will combine research and production of biotechnology drugs and employ 250 people. The pharmaceutical company has invested more than 250 million Swiss francs in this “Biotech Development Centre”. It is dedicated to the development and production of active ingredients for clinical…

Read More

BIO US – Philadelphia

BIO US 2024

BIO International Convention, the premier event for the biotechnology industry, takes place from 7 to 10 June 2027 in Philadelphia (USA) The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.Whether you work at a public pharmaceutical company, biotech…

Read More

Selexis SA and KBI Biopharma now operate as one organisation

Selexis - KBI

Selexis, an EFPL startup, was founded in 2001 before being acquired by the Japanese group JSR Life Sciences. KBI Biopharma, another company owned by JSR, inaugurated its factory in 2022 at Plan les Ouates in Geneva and from now on operates as one with Selexis. The activity is consolidated under the KBI Biopharma name.  …

Read More

Lonza acquires Dutch biotech company Synaffix

Ibex™ Lonza facilit in Visp Switzerland

The Valais-based pharmaceutical subcontractor will pay an initial €100 million, with subsequent milestone payments of up to a further €60 million.     The deal will strengthen Lonza’s portfolio of antibody-drug conjugates (ADCs) through the integration of Synaffix’s platform. According to a recent estimate relayed by Lonza, the ADC market is set to pass the…

Read More

Driving Growth and Innovation: Yassin Nahi’s Insights on the Biotech Cluster in Western Switzerland

Yassin Nahi GGBa

The Swiss Biotech Report 2023 recently unveiled an impressive portrait of Switzerland’s thriving biotech sector. With record revenues of CHF 6.8 billion (USD 7.5 billion), and fundraising of CHF 1.3 billion (USD 1.5 billion), the report highlighted the remarkable growth and resilience of Switzerland amidst global challenges. Indeed, with approximately 47,000 employees, the industry serves as…

Read More

CSEM and MOMM Diagnostics partner to develop a rapid test for preeclampsia

CSEM and MOMM Diagnostics

Among the various pregnancy complications, one of the most serious and potentially life-threatening conditions is preeclampsia affecting 3 to 8% of pregnant women. It is characterized by high blood pressure and protein leakage in the urine, which can lead to kidney failure, liver failure, seizures, stroke and even death. Women with a family history of…

Read More

How the flu virus hacks our cells

Virus Grippe

A UNIGE team has discovered how the influenza A virus hijacks the mechanism for importing iron into cells to invade its host.   Influenza epidemics, caused by influenza A or B viruses, result in acute respiratory infection. They kill half a million people worldwide every year. These viruses can also wreak havoc on animals, as…

Read More

Impossible Materials wins CHF 150,000

Impossible Materials

After raising CHF 3.8 Million last month, the Fribourg-based startup won the third and final stage of the Venture Kick programme.  The company develops sustainable, cellulose-based white pigments that could replace titanium dioxide (TiO2).   The startup also creates other plant-based ingredients for a broad range of industrially manufactured products that allow for more sustainable…

Read More